Антифосфолипидный синдром - Насонов Е.Л.
ISBN 5-98216-010-5
Скачать (прямая ссылка):
15. Giles IP, Isenberg DA, Latchman DS, Rahman A. How do antiphospholipid antibodies bind to ?2- glycoprotein I. Arthritis Rheum 2003; 48: 2111—2121.
16. Bouma B, de Groot PG, van den Elsen JM, Ravelli RB, Schouten A, Simmelink MJ, Derksen RH, Kroon J, Gros P. Adhesion mechanism of
S
100
S-
SHS-OOO4.qxd 21.11.2006 16:56 Page 1001
01
ГЛАВА 5. Патогенетические механизмы антифосфолипидного синдрома
human ?2-glycoprotein I to phospholipids based on its crystal structure. EMBO J1999; 18: 5166— 5174.
17. Schwarzenbacher R, Zeth K, Diederichs K, Gries A, Kostner GM, Laggner P, Prassl R. Crystal structure of human ?2-glycoprotein I: implications for phospholipid binding and the antiphospholipid syndrome. EMBO J 1999; 18: 6228—6239.
18. Lutters BCH, de Droot P, Derksen RHWM. ?2-glycoprotein 1 — a key player in the antiphospholipid syndrome. JMAJ 2002; 4 (Suppl): 958— 962.
19. Hunt J, Krilis S. The fifth domain of beta2-glycoprotein I containes a phosphilipid binding site (cys281-cys288), and region recognised by anti-cardiolipin antibodies. J Immunol 1994; 152: 653—659.
20. Kertesz Z, Yu B, Steinkasserer A, et al. Characterization of binding of human beta2-gly-coprotein I to cardiolipin. Biochem J 1995; 310:315—321.
21. Wurm H. Beta2-glycoprotein I (apol-ipoprotein H) interactions with phospholipid vesicles. Int J Biochem 1984; 16: 511—515.
22. Kochl S, Fresser F, Lobentanz E, et al. Novel interaction of apolipoprotein (a) with ?2-glycoprotein I mediated by the kringle IVdomain. Blood 1997; 90: 1482—1489.
23. Rojkjaer R, Klaerke DA, Schousboe I. Characterisation of the interaction between ?2-glycoprotein I and calmodulin, and identification of the binding sequence in ?2-glycoprotein I. Biochem Biophys, Acta Protein Struct Mol Enzymol 1997; 1339: 217—225.
24. Ma K, Zhang J-C. Wan K, et al. The binding of ?2-glycoprotein I (?2-GPI) to endothelial cells mediated through a high affinity interaction with annexin II. Blood 1998; 92L; 172A.
25. Chonn A, Semple SC, Cullis PR. ?2-glyco-protein I is a major protein associated with very rapidly cleared liposomes in vitro, suggesting a significant role in the immune clerance of "non-self particles J Biol Chem 1995; 270:25845-25849.
26. Balasubramanian K, Chandra J, Schroit AJ. Immune clearance of phosphatidylserine-expressing cells by phagocytes. The role of ?2-gly-coprotein I is macrophage recognition. J Biol Chem 1997; 272: 31113—31117.
27. Borchman D, Harris EN, Pierangelli SS, Lamba OP. Interactions and molecular structure of cardiolipin and beta2-glycoprotein 1 (beta2-GP1). Clin Exp. Immunol 1995; 102:37.
28. Chonn A, Semple SC, Cullis PR. ?2-Glycoprotein I is a major protein associated with very rapidly cleared liposomes in vivo, suggesting a significant role in the immune clearance of "non-self'particles. J Biol Chem 1995; 270: 25845—25849.
29. Manfredi AA, Rovere P, Galati G, Heltai S, Bozzolo E, Soldini L, Davoust J, Balestrieri G, Tincani A, Sabbadini MG. Apoptotic cell clearance in systemic lupus erythematosus, I: opsoniza-tion by antiphospholipid antibodies. Arthritis Rheum 1998; 41: 205—214.
30. Merten M, Motamedy S, Ramamuthy S, et al. Sulfatides. Targets for antiphospholipid antibodies. Circulation 2003; 108: 2082—2087.
31. Cleve H. Genetic studies on the deficiency of b2glycoprotein I of human serum. Humangenetik 1968; 5: 294—304.
32. Yasuda S, Tsutsumi A, Chiba H, Yanai H, Miyoshi Y, Takeuchi R, Horita T, Atsumi T, Ichikawa K, Matsuura E, Koike T. ?2-Glycopro-tein I deficiency: prevalence, genetic background and effects on plasma lipoprotein metabolism and hemostasis. Atherosclerosis 2000; 152: 337—346.
33. Bancsi LF, van der Linden IK, Bertina RM. ?2-Glycoprotein I deficiency and the risk of thrombosis. Thromb Haemost 1992; 67: 649— 653.
34. Sheng Y, Reddel SW, Herzog H, Wang YX, Brighton T, France MP, Robertson SA, Krilis SA. Impaired thrombin generation in ?2-glycoprotein I null mice. J Biol Chem 2001; 276: 13817— 13821.
35. Gharavi AE, Sammaritano LR, Wen J, Elkon KB. Induction of antiphospholipid antibodies by immunization with ?2-glycoprotein I (apolipoprotein H). J Clin Invest 1992; 90: 1105—1109.
36. Gharavi AE, Sammaritano LR, Bovastro JL, Wilson WA. Specificities and characteristics of ?2-glycoprotein I induced antiphpspholipid antibodies. J Lab Clin Med 1995; 125: 775— 778.
37. Reddel SW, Wang YX, Sheng YH, Krilis SA. Epitope studies with anti-?2-glycoprotein I anti-
SHS-OOO4.qxd 21.11.2006 16:56 Page 102"
02
Насонов Е.Л. Антифосфолипидный синдром.
bodies from autoantibody and immunized sources. J Autoimmun 2000; 15: 91—96.
38. McNeeley PA, Dlott JS, Furie RA, Jack RM, Ortel TL, Triplett DA, Victoria EJ, Linnik MD. ?2-Glycoprotein I-dependent anticardi-olipin antibodies preferentially bind the amino terminal domain of ?2-glycoprotein I. Thromb Haemost 2001; 86: 590—595.
39. Палькеева МЕ, Сидорова МВ, Кузнецова ТВ, Кобылянский АГ, Тищенко ВА, Насонов ЕЛ, Беспалова ЖД, Евстигнеева РП. Синтез и исследование антигенных свойств пептидных фрагментов бета2-гликопротеи-на-I. Биоорганическая химия, 1996; 9: 678— 685.
